期刊文献+

高密度脂蛋白功能研究进展 被引量:16

下载PDF
导出
摘要 高密度脂蛋白(HDL)是由脂质和脂蛋白组成的复合体,功能复杂、容易变异。正常的HDL具有保护心血管的作用,但应用胆固醇酯转移蛋白抑制剂和烟酸升高血浆HDL胆固醇(HDL-C)水平并不能降低心血管事件发生率。提示可能是HDL功能而不是HDL-C水平起关键作用。研究发现冠心病、糖尿病、慢性肾病、风湿性关节炎和心脏外科手术等疾病状态会使HDL功能发生改变,不但不具有保护心血管的作用,而且对心血管有损害,称为趋炎HDL或功能异常HDL。趋炎HDL与正常HDL成分不同,它逆向转运胆固醇的能力下降,抗炎抗氧化能力受损,可损伤血管内皮功能。运动、载脂蛋白A-I模拟肽、辛伐他汀等可部分改善HDL功能。因此,有关HDL的研究更应关注HDL功能和其成份在疾病中的改变、如何改变机体内环境,防止新生HDL转变为趋炎HDL,以及如何改善这些HDL的功能,使其恢复保护心血管的特性。
出处 《中国循环杂志》 CSCD 北大核心 2015年第9期919-921,共3页 Chinese Circulation Journal
基金 国家杰出青年科学基金(81325001) 国家自然科学基金项目(81170271,81370370) 教育部长江学者资助计划 广东省高等学校高层次人才项目
  • 相关文献

参考文献43

  • 1Downs JR, Clearfield M, Weis S, et el. Primary prevention of acute coronary events with lovastatin in Inet alia women with average cholesterol levels: Results of afcaps/texcaps. Air force/texas coronav'y atheroselerosis prevention siudy. JAMA, 1998, 279: 1615-1622.
  • 2Norata GD, Callegari E, Marchesi M, el al. High-density lipoproteins induce transforming growth factor-hela2 expression in endo|helial cells. Circulation, 2005, 111:2805-2811.
  • 3Vickers KC, Pahnisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to reeipient cells by high-density lipoproteins. Nat Cell Bicol, 2011, 13: 423-433.
  • 4Kastelein J J, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med, 2007, 356: 1620-1630.
  • 5Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of lorcetrapiB on the progression of coronary atheroselerosis. N Engl J Meet, 2007, 356: 1304-1316.
  • 6Bots ML, Visseren FL, Evans GW, et al. Torcetrapih and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study):a randomised, double-blind trial. Lancet, 2007, 370:153-160.
  • 7Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor toreetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation, 2008, 118: 2515-2522.
  • 8Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007, 357: 2109-2122.
  • 9Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012, 367: 2089-2099.
  • 10Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011,365: 2255-2267.

二级参考文献36

  • 1严晓伟,包婺平.疾病状态下高密度脂蛋白的功能缺陷[J].中国循环杂志,2007,22(2):152-154. 被引量:7
  • 2Anantharamaiah G, Navab M, Reddy ST, et al. Synthetic peptides: managing lipid disorders. CUIT Opin Lipidol, 2006, 17: 233-237.
  • 3Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009, 302: 1993- 2000.
  • 4Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high?density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation, 2004,109:3215-3220.
  • 5Navab M, Anantharamaiah GM, Hama S, et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vase Bioi, 2005, 25: 1426-1432.
  • 6Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation, 2003, 107: 2337-2341.
  • 7Peterson SJ, Kim DH, Li M, et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-I, pAMPK, and pAKT in obese mice. J Lipid Res, 2009, 50: 1293-1304.
  • 8Imaizumi S, Grijalva V, Navab M, et al. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti?inflammatory HDL in mice. Drug Metab Lett, 2010, 4: 139-148.
  • 9Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation, 2003,107: 2337-2341.
  • 10Arsenault BJ, Boekholdt SM, Kastelein JJ. Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol, 2011, 8: 197-206.

共引文献14

同被引文献185

引证文献16

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部